Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers

Abstract

The expression profile of a panel of 15 cAMP phosphodiesterase isoforms was determined for inflammatory cell types of relevance to chronic obstructive pulmonary disease (COPD). In particular, the expression profiles for bronchoalveolar macrophages, peripheral blood monocytes, T lymphocytes, and neutrophils from smokers with and without COPD were compared. The phosphodiesterase expression profile was also analyzed for peripheral blood monocytes, T lymphocytes, and neutrophils from nonsmokers and compared with smokers. Qualitative RT-PCR identified transcripts for PDE4A10, PDE4A7, PDE4B1, PDE4B2, PDE4D1, and PDE4D2 isoforms as well as transcripts for both PDE3B and PDE7A in T cells, monocytes, and macrophages in all subjects. Transcripts for PDE4B3 and PDE4D4 were not observed in any of the cell types investigated. PDE4C was detected in all cells analyzed except for T cells. The long PDE4A4, PDE4D3, and PDE4D5 isoforms exhibited cell type-specific expression patterns. Semiquantitative and real-time quantitative RT-PCR were used to analyze differential expression between disease states and between cell types. PDE4A4 was found significantly upregulated in lung macrophages from smokers with COPD when compared with control smokers. Furthermore, PDE4A4 as well as PDE4B2 transcripts were detected in higher amounts in peripheral blood monocytes of smokers when compared with nonsmokers. Finally, PDE4D5 and PDE4C were differentially regulated in lung macrophages when compared with monocytes of the same subjects, irrespective of the disease state. The data obtained suggest that PDE4A4 may be relevant as a macrophage-specific anti-inflammatory target for COPD.

Cystic Fibrosis Transmembrane Conductance Regulator Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic Bronchitis

“…The cAMP-selective PDE4 family is a major isoform found in respiratory epithelia and in resident immune cells of the lung (13,14). Roflumilast is a PDE4-selective inhibitor that improves lung function and the number of pulmonary exacerbations in patients with COPD, although this effect is seen only in patients with chronic bronchitis and frequent exacerbations (15).…”

Stability of housekeeping genes in alveolar macrophages from COPD patients

“…Gene expression assays for alveolar macrophages have been performed to investigate their role in pathogenesis [11,12]. Although it is important to know whether the stability of housekeeping genes in alveolar macrophages is affected by various culture conditions or by differences in the severity of lung disease, these data are currently unavailable.…”

Apremilast: target synthetic drug for the treatment of psoriatic arthritis and psoriasis

“…Она имеет четыре подтипа (А, B, С, D) и выявляется в эпителиальных клетках дыха-тельных путей, клетках кожи, гладких мышцах, эндотелии сосудов и хондроцитах [14]. Кроме того, ФДЭ-4 экспрес-сируется иммунными клетками, включая дендритные клетки (ДК), Т-клетки, макрофаги и моноциты [15][16][17]. Ингибиторы ФДЭ-4 вызывают накопление внутриклеточ-ного циклического аденозинмонофосфата (цАМФ), что приводит к ингибированию транскрипции провоспали-тельных цитокинов и других клеточных реакций, таких как дегрануляция нейтрофилов, хемотаксис и адгезия к эндотелиальным клеткам [18] (табл.…”